Cover Image

De Novo versus secondary metastatic EGFR-mutated non-small-cell lung cancer

Background: Metastatic epidermal growth factor receptor-mutated (EGFR)+ non-small-cell lung cancer (NSCLC) can present de novo or following previous nonmetastatic disease ("secondary"). Potential differences between these two patient subsets are unclear at present. Methods: We retrospectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Bozorgmehr, Farastuk (Author) , Kazdal, Daniel (Author) , Chung, Inn (Author) , Kirchner, Martina (Author) , Magios, Nikolaus (Author) , Kriegsmann, Mark (Author) , Allgäuer, Michael (Author) , Klotz, Laura Valentina (Author) , Muley, Thomas (Author) , El-Shafie, Rami (Author) , Fischer, Jürgen (Author) , Faehling, Martin (Author) , Stenzinger, Albrecht (Author) , Thomas, Michael (Author) , Christopoulos, Petros (Author)
Format: Article (Journal)
Language:English
Published: 09 April 2021
In: Frontiers in oncology
Year: 2021, Volume: 11, Pages: 1-9
ISSN:2234-943X
DOI:10.3389/fonc.2021.640048
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fonc.2021.640048
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2021.640048/full
Get full text
Author Notes:Farastuk Bozorgmehr, Daniel Kazdal, Inn Chung, Martina Kirchner, Nikolaus Magios, Mark Kriegsmann, Michael Allgäuer, Laura V. Klotz, Thomas Muley, Rami A. El Shafie, Jürgen R. Fischer, Martin Faehling, Albrecht Stenzinger, Michael Thomas and Petros Christopoulos
Description
Summary:Background: Metastatic epidermal growth factor receptor-mutated (EGFR)+ non-small-cell lung cancer (NSCLC) can present de novo or following previous nonmetastatic disease ("secondary"). Potential differences between these two patient subsets are unclear at present. Methods: We retrospectively analyzed characteristics of tyrosine kinase inhibitor (TKI)-treated patients with de novo vs. secondary metastatic EGFR+ NSCLC until December 2019 (n=401). Results: De novo metastatic disease was 4x more frequent than secondary (n=83/401), but no significant differences were noted regarding age (median 66 vs. 70 years), sex (65% vs. 65% females), smoking history (67% vs. 62% never/light-smokers), and histology (both greater than 95% adenocarcinoma). Patients with secondary metastatic disease showed a better ECOG performance status (PS 0-1 67%-32% vs. 46% 52%, p=0.003), fewer metastatic sites (mean 1.3 vs. 2.0, p less than 0.001), and less frequent brain involvement (16% vs. 28%, p=0.022) at the time of stage IV diagnosis. Progression-free survival (PFS) under TKI (median 17 for secondary vs. 12 months for de novo, p=0.26) and overall survival (OS, 29 vs. 25 months, respectively, p=0.47) were comparable. EGFR alterations (55% vs. 60% exon 19 deletions), TP53 mutation rate at baseline (47% vs. 43%, n=262), and T790M positivity at the time of TKI failure (51% vs. 56%, n=193) were also similar. OS according to differing characteristics, e.g. presence or absence of brain metastases (19-20 or 30-31 months, respectively, p=0.001), and ECOG PS 0 or 1 or 2 (32-34 or 20-23 or 5-7 months, respectively, p less than 0.001), were almost identical for de novo and secondary metastatic disease. Conclusions: Despite the survival advantage reported in the pre-TKI era for relapsed NSCLC, molecular features and outcome of TKI-treated metastatic EGFR+ tumors are currently independent of preceding nonmetastatic disease. This simplifies design of outcome studies and can assist prognostic considerations in everyday management of patients with secondary metastatic EGFR+ tumors.
Item Description:Gesehen am 17.05.2021
Physical Description:Online Resource
ISSN:2234-943X
DOI:10.3389/fonc.2021.640048

Similar Items